![](https://cdn.benzinga.com/files/images/story/2025/02/12/EW.png?width=1200&height=800&fit=crop)
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups. Adjusted earnings per share came in at 59 …